- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Heron Therapeuti (HRTX)
Heron Therapeuti stock price live, this page displays NASDAQ HRTX stock exchange data. View the HRTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Heron Therapeuti real time stock price chart below.
What Is the Heron Therapeuti Stock Price Today?
The Heron Therapeuti stock price today is 1.350.
What Is the Stock Symbol for Heron Therapeuti?
The stock symbol for Heron Therapeuti is ""HRTX.""
What Stock Exchange Does Heron Therapeuti Trade On?
Heron Therapeuti is listed and trades on the NASDAQ stock exchange.
Is Heron Therapeuti a Good Stock to Buy?
Determining whether Heron Therapeuti—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HRTX quote. (ISIN: US4277461020)
What Is the Heron Therapeuti Stock Price Today?
The Heron Therapeuti stock price today is 1.350.
What Is the Stock Symbol for Heron Therapeuti?
The stock symbol for Heron Therapeuti is ""HRTX.""
What Stock Exchange Does Heron Therapeuti Trade On?
Heron Therapeuti is listed and trades on the NASDAQ stock exchange.
Is Heron Therapeuti a Good Stock to Buy?
Determining whether Heron Therapeuti—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HRTX quote. (ISIN: US4277461020)
Fair Value
An estimate of a Heron Therapeuti's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.340
1.420
52 wk Range
1.040
2.680
HRTX Scorecard
Full Analysis
Short term obligations exceed liquid assets
HRTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Heron Therapeuti's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.3401.420
52 wk Range
1.0402.680
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
HRTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Heron Therapeuti's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
4.750
Upside
+251.85%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Heron Therapeuti Company Profile
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
Heron Therapeuti Earnings Call Summary for Q2/2025
- Heron Therapeutics missed Q2 2025 EPS (-0.02 USD vs -0.01 USD expected) and revenue ($37.2M vs $38.08M forecast), stock dropped 21.2% pre-market
- Company transitioned to net income YTD despite quarterly miss; gross profit margin increased to 73.5% from 70.8% in previous quarter
- Maintained net revenue guidance of $153-163M for the year, revised adjusted EBITDA guidance to $9-13M; expects inventory normalization in Q3
- CEO highlighted strategy execution and financial strengthening; COO noted sales force optimization and creation of dedicated teams for key products
- Analysts questioned Zenerlef 400mg transition impact and J-code reimbursement benefits; company addressed inventory adjustments and sales restructuring
Last Updated: 08/08/2025, 15:28
Read Full TranscriptCompare HRTX to Peers and Sector
Metrics to compare | HRTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHRTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −222.3x | −0.5x | −0.5x | |
PEG Ratio | −2.35 | −0.02 | 0.00 | |
Price/Book | −7.6x | 2.4x | 2.6x | |
Price / LTM Sales | 1.4x | 8.1x | 3.3x | |
Upside (Analyst Target) | 259.7% | 309.8% | 38.9% | |
Fair Value Upside | Unlock | 18.8% | 5.4% | Unlock |
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 4.750
(+251.85% Upside)
Earnings
Latest Release
Aug 08, 2025
EPS / Forecast
-0.02 / -0.01
Revenue / Forecast
37.20M / 38.08M
People Also Watch
FAQ
What Stock Exchange Does Heron Therapeuti Trade On?
Heron Therapeuti is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Heron Therapeuti?
The stock symbol for Heron Therapeuti is "HRTX."
What Is the Heron Therapeuti Market Cap?
As of today, Heron Therapeuti market cap is 209.24M.
What Is Heron Therapeuti's Earnings Per Share (TTM)?
The Heron Therapeuti EPS (TTM) is -0.01.
When Is the Next Heron Therapeuti Earnings Date?
Heron Therapeuti will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is HRTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Heron Therapeuti Stock Split?
Heron Therapeuti has split 2 times.
How Many Employees Does Heron Therapeuti Have?
Heron Therapeuti has 122 employees.
What is the current trading status of Heron Therapeuti (HRTX)?
As of 30 Aug 2025, Heron Therapeuti (HRTX) is trading at a price of 1.350, with a previous close of 1.39. The stock has fluctuated within a day range of 1.340 to 1.420, while its 52-week range spans from 1.040 to 2.680.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.